Efficacy and Safety of Apremilast in Systemic-and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
J Bagel, M Lebwohl, JM Jackson, R Chen… - Journal of drugs in …, 2018 - europepmc.org
BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
Efficacy and safety of apremilast in systemic-and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL
LF Stein Gold, J Bagel… - … of drugs in …, 2018 - scholarlycommons.henryford.com
BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
Efficacy and Safety of Apremilast in Systemic-and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL
LS Gold, J Bagel, M Lebwohl… - Journal of drugs in …, 2018 - pubmed.ncbi.nlm.nih.gov
BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …